IgEnio® is a flexible therapy option for patients suffering from severe stages of allergic symptoms. It selectively removes type IgE antibodies from the plasma in a single treatment. IgEnio® presents a valuable therapy option for patients with high IgE levels, where conventional treatments prove ineffective.
IgEnio® uses a specific ligand with high affinity for IgE
After separation from other blood components, the plasma is passed through the IgEnio® adsorber column, where IgE binds to ScFv12. ScFv12 is an anti-IgE antibody-derived single-chain fragment with a high affinity for human IgE.